Patrik Medstrand

List of Publications by Year
in descending order

63	1,311	394390 19	395678 33
papers	citations	h-index	g-index

64	64	64	1749
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Molecular Epidemiology and Transmission Dynamics of the HIV-1 Epidemic in Ethiopia: Epidemic Decline Coincided With Behavioral Interventions Before ART Scale-Up. Frontiers in Microbiology, 2022, 13, 821006.	3.5	1
2	Airborne Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Hospitals: Effects of Aerosol-Generating Procedures, HEPA-Filtration Units, Patient Viral Load, and Physical Distance. Clinical Infectious Diseases, 2022, 75, e89-e96.	5.8	24
3	Detection of SARS-CoV-2 RNA on surfaces in a COVID-19 hospital ward indicates airborne viral spread. Journal of Hospital Infection, 2022, 124, 121-122.	2.9	2
4	Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia. Viruses, 2022, 14, 729.	3.3	8
5	SARS-CoV-2 in Exhaled Aerosol Particles from COVID-19 Cases and Its Association to Household Transmission. Clinical Infectious Diseases, 2022, 75, e50-e56.	5.8	20
6	All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study. Clinical Infectious Diseases, 2021, 72, 2079-2086.	5.8	46
7	Drug Resistance in HIV-Positive Adults During the Initial Year of Antiretroviral Treatment at Ethiopian Health Centers. Open Forum Infectious Diseases, 2021, 8, ofab106.	0.9	1
8	Associations Between Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid Levels and Incidence of Invasive Cancer in People With HIV After Initiation of Combination Antiretroviral Therapy. Open Forum Infectious Diseases, 2021, 8, ofab131.	0.9	2
9	Inverted CD8 T-Cell Exhaustion and Co-Stimulation Marker Balance Differentiate Aviremic HIV-2-Infected From Seronegative Individuals. Frontiers in Immunology, 2021, 12, 744530.	4.8	5
10	High level of HIV drug resistance and virological non-suppression among female sex workers in Ethiopia. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, .	2.1	2
11	Interferon-Î³-Inducible Protein 10 (IP-10) Kinetics after Antiretroviral Treatment Initiation in Ethiopian Adults with HIV. Microbiology Spectrum, 2021, 9, e0181021.	3.0	2
12	Sources of Airborne Norovirus in Hospital Outbreaks. Clinical Infectious Diseases, 2020, 70, 2023-2028.	5.8	54
13	Aerosolization and recovery of viable murine norovirus in an experimental setup. Scientific Reports, 2020, 10, 15941.	3.3	9
14	Exhaled respiratory particles during singing and talking. Aerosol Science and Technology, 2020, 54, 1245-1248.	3.1	170
15	The HIV care continuum and HIV-1 drug resistance among female sex workers: a key population in Guinea-Bissau. AIDS Research and Therapy, 2020, 17, 33.	1.7	8
16	HIV treatment in Guinea-Bissau: room for improvement and time for new treatment options. AIDS Research and Therapy, 2020, 17, 3.	1.7	4
17	Brief Report: Interferon-Î³â€“Inducible Protein 10â€”A Potential Marker for Targeted Viral Load Monitoring of Antiretroviral Treatment?. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 475-478.	2.1	3
18	Socio-economic condition and lack of virological suppression among adults and adolescents receiving antiretroviral therapy in Ethiopia. PLoS ONE, 2020, 15, e0244066.	2.5	7

#	Article	IF	Citations
19	Title is missing!. , 2020, 15, e0244066.		0
20	Title is missing!. , 2020, 15, e0244066.		0
21	Title is missing!. , 2020, 15, e0244066.		0
22	Title is missing!. , 2020, 15, e0244066.		0
23	Title is missing!. , 2020, 15, e0244066.		0
24	Title is missing!. , 2020, 15, e0244066.		0
25	A17â€ƒThe effect of intra-host evolution of HIV-2 capsid on disease progression. Virus Evolution, 2019, 5, .	4.9	0
26	HIV-2 as a model to identify a functional HIV cure. AIDS Research and Therapy, 2019, 16, 24.	1.7	24
27	New insights are game-changers in HIV-2 disease management â€“ Authors' reply. Lancet HIV,the, 2019, 6, e214-e215.	4.7	4
28	Hydrogen peroxide vapour treatment inactivates norovirus but has limited effect on post-treatment viral RNA levels. Infectious Diseases, 2019, 51, 197-205.	2.8	10
29	Is lowâ€level <scp>HIV</scp>â€1 viraemia associated with elevated levels of markers of immune activation, coagulation and cardiovascular disease?. HIV Medicine, 2019, 20, 571-580.	2.2	19
30	Transmission dynamics study of tuberculosis isolates with whole genome sequencing in southern Sweden. Scientific Reports, 2019, 9, 4931.	3.3	21
31	Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study. Lancet HIV,the, 2019, 6, e25-e31.	4.7	57
32	Low Postseroconversion CD4 + T-cell Level Is Associated with Faster Disease Progression and Higher Viral Evolutionary Rate in HIV-2 Infection. MBio, 2019, 10, .	4.1	7
33	Quantification of HIV-2 DNA in Whole Blood. Bio-protocol, 2019, 9, e3404.	0.4	1
34	Protease Inhibitors or NNRTIs as First-Line HIV-1 Treatment in West Africa (PIONA): A Randomized Controlled Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 386-393.	2.1	11
35	Prevalence of HIV-1 pretreatment drug resistance among treatment naÃ¯ve pregnant women in Bissau, Guinea Bissau. PLoS ONE, 2018, 13, e0206406.	2.5	11
36	HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003-2013. PLoS ONE, 2018, 13, e0205446.	2.5	22

#	Article	IF	Citations
37	Molecular epidemiology of HIV-1 in Iceland: Early introductions, transmission dynamics and recent outbreaks among injection drug users. Infection, Genetics and Evolution, 2017, 49, 157-163.	2.3	19
38	Development of an algorithm for determination of the likelihood of virological failure in HIV-positive adults receiving antiretroviral therapy in decentralized care. Global Health Action, 2017, 10, 1371961.	1.9	3
39	Genetic characterization of human immunodeficiency virus type 1 transmission in the Middle East and North Africa. Heliyon, 2017, 3, e00352.	3.2	11
40	Decreasing prevalence of transmitted drug resistance among ART-naive HIV-1-infected patients in Iceland, 1996â€“2012. Infection Ecology and Epidemiology, 2017, 7, 1328964.	0.8	6
41	Long-term Outcome of Antiretroviral Treatment in Patients With and Without Concomitant Tuberculosis Receiving Health Centerâ€“Based Careâ€”Results From a Prospective Cohort Study. Open Forum Infectious Diseases, 2017, 4, ofx219.	0.9	13
42	Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment. PLoS ONE, 2017, 12, e0180761.	2.5	52
43	Hydrogen Peroxide Vapor Decontamination in a Patient Room Using Feline Calicivirus and Murine Norovirus as Surrogate Markers for Human Norovirus. Infection Control and Hospital Epidemiology, 2016, 37, 561-566.	1.8	17
44	HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries. Virus Evolution, 2016, 2, vew010.	4.9	68
45	Cocirculation of Several Similar But Unique HIV-1 Recombinant Forms in Guinea-Bissau Revealed by Near Full-Length Genomic Sequencing. AIDS Research and Human Retroviruses, 2015, 31, 938-945.	1.1	3
46	High rates of viral suppression in a cohort of HIV-positive adults receiving ART in Ethiopian health centers irrespective of concomitant tuberculosis. Journal of the International AIDS Society, 2014, 17, 19612.	3.0	3
47	High Rates of Virological Suppression in a Cohort of Human Immunodeficiency Virus-Positive Adults Receiving Antiretroviral Therapy in Ethiopian Health Centers Irrespective of Concomitant Tuberculosis. Open Forum Infectious Diseases, 2014, 1, ofu039.	0.9	16
48	Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. Aids, 2014, 28, 949-957.	2.2	32
49	The origin and emergence of an HIV-1 epidemic. Aids, 2014, 28, 1031-1040.	2.2	13
50	Consensus HIV-1 subtype A integrase and its raltegravir-resistant variants: Design and characterization of the enzymatic properties. Biochimie, 2014, 102, 92-101.	2.6	8
51	Faster Progression to AIDS and AIDS-Related Death Among Seroincident Individuals Infected With Recombinant HIV-1 A3/CRF02_AG Compared With Sub-subtype A3. Journal of Infectious Diseases, 2014, 209, 721-728.	4.0	33
52	Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. Aids, 2014, 28, 949-57.	2.2	9
53	High intrapatient HIV-1 evolutionary rate is associated with CCR5-to-CXCR4 coreceptor switch. Infection, Genetics and Evolution, 2013, 19, 369-377.	2.3	18
54	Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness. Human Vaccines and Immunotherapeutics, 2013, 9, 2103-2110.	3.3	3

#	Article	IF	Citations
55	Inhibition of HIV-1 Disease Progression by Contemporaneous HIV-2 Infection. New England Journal of Medicine, 2012, 367, 224-232.	27.0	94
56	HIV-1 Molecular Epidemiology in Guinea-Bissau, West Africa: Origin, Demography and Migrations. PLoS ONE, 2011, 6, e17025.	2.5	55
57	Human immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance. Journal of Internal Medicine, 2011, 270, 520-531.	6.0	14
58	Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.5	39
59	Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease - indication of an evolving epidemic in West Africa. Retrovirology, 2010, 7, 23.	2.0	80
60	Frequent Intrapatient Recombination between Human Immunodeficiency Virus Type 1 R5 and X4 Envelopes: Implications for Coreceptor Switch. Journal of Virology, 2007, 81, 3369-3376.	3.4	48
61	Isolation of human immunodeficiency virus-type 1 (HIV-1) clones with biological and molecular properties of the primary isolate. Virology, 2006, 350, 58-66.	2.4	8
62	Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. Journal of General Virology, 2005, 86, 2859-2869.	2.9	56
63	Structure and genomic organization of a novel human endogenous retrovirus family: HERV-K (HML-6).. Journal of General Virology, 1997, 78, 1731-1744.	2.9	35